PMID- 24660840
OWN - NLM
STAT- MEDLINE
DCOM- 20140527
LR  - 20220317
IS  - 1557-7449 (Electronic)
IS  - 1087-2914 (Print)
IS  - 1087-2914 (Linking)
VI  - 28
IP  - 4
DP  - 2014 Apr
TI  - Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in 
      treatment-naive HIV-1-infected patients with HIV-1 RNA </=100,000 copies/mL: week 
      96 pooled ECHO/THRIVE subanalysis.
PG  - 168-75
LID - 10.1089/apc.2013.0310 [doi]
AB  - The once daily, single-tablet regimen (STR) combining rilpivirine (RPV), 
      emtricitabine (FTC), and tenofovir disoproxil fumarate (TDF) provides a 
      simplified treatment option for antiretroviral therapy (ART)-naive patients with 
      baseline HIV-1 RNA (BLVL) of </=100,000 copies/mL. The aim of this analysis is to 
      compare long-term efficacy, safety, and tolerability of RPV+FTC/TDF vs. efavirenz 
      (EFV)+FTC/TDF as individual components in subjects with BLVL </=100,000 copies/mL. 
      Week 96 efficacy and safety data from subjects with BLVL </=100,000 copies/mL, who 
      received daily RPV 25 mg or EFV 600 mg with FTC/TDF in the phase 3, randomized, 
      double-blind, double-dummy, active-controlled, registrational trials ECHO and 
      THRIVE, were analyzed. Virologic response was evaluated by intent-to-treat, time 
      to loss of virological response (ITT-TLOVR), and Snapshot algorithms. Through 
      Week 96, RPV+FTC/TDF demonstrated non-inferior efficacy to EFV+FTC/TDF (84% vs. 
      81%, respectively; ITT-TLOVR) in 543 subjects with BLVL </=100,000 copies/mL, and 
      overall rates of virologic failure (VF) were 5.9% vs. 2.4%, respectively. 
      Resistance development was lower in Year 2 than Year 1. Subjects in both arms 
      with suboptimal adherence (</=95%) had lower virologic responses (63% vs. 62%, 
      respectively). Treatment with RPV+FTC/TDF was associated with significantly fewer 
      treatment-related adverse events (AEs), grade 2-4 AEs, neurological and 
      psychiatric AEs (including dizziness and abnormal dreams/nightmares), and rash. 
      Additionally, grade 2-4 treatment-emergent laboratory abnormalities and grade 1-3 
      lipid abnormalities were significantly less common with RPV+FTC/TDF than 
      EFV+FTC/TDF. RPV+FTC/TDF demonstrated non-inferior efficacy to EFV+FTC/TDF in 
      ART-naive subjects with BLVL </=100,000 copies/mL and was associated with a higher 
      rate of VF but a more favorable safety and tolerability profile through Week 96.
FAU - Behrens, Georg
AU  - Behrens G
AD  - 1 Hanover Medical School , Hanover, Germany .
FAU - Rijnders, Bart
AU  - Rijnders B
FAU - Nelson, Mark
AU  - Nelson M
FAU - Orkin, Chloe
AU  - Orkin C
FAU - Cohen, Calvin
AU  - Cohen C
FAU - Mills, Anthony
AU  - Mills A
FAU - Elion, Richard A
AU  - Elion RA
FAU - Vanveggel, Simon
AU  - Vanveggel S
FAU - Stevens, Marita
AU  - Stevens M
FAU - Rimsky, Laurence
AU  - Rimsky L
FAU - Thorpe, David
AU  - Thorpe D
FAU - Bosse, Matthew
AU  - Bosse M
FAU - White, Kirsten
AU  - White K
FAU - Zhong, Lijie
AU  - Zhong L
FAU - DeMorin, Jennifer
AU  - DeMorin J
FAU - Chuck, Susan K
AU  - Chuck SK
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20140324
PL  - United States
TA  - AIDS Patient Care STDS
JT  - AIDS patient care and STDs
JID - 9607225
RN  - 0 (Alkynes)
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Antiviral Agents)
RN  - 0 (Benzoxazines)
RN  - 0 (Cyclopropanes)
RN  - 0 (Nitriles)
RN  - 0 (Organophosphonates)
RN  - 0 (Pyrimidines)
RN  - 0 (RNA, Viral)
RN  - 0 (Reverse Transcriptase Inhibitors)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 99YXE507IL (Tenofovir)
RN  - FI96A8X663 (Rilpivirine)
RN  - G70B4ETF4S (Emtricitabine)
RN  - JAC85A2161 (Adenine)
RN  - JE6H2O27P8 (efavirenz)
SB  - IM
MH  - Adenine/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Alkynes
MH  - Anti-HIV Agents/administration & dosage/*therapeutic use
MH  - Antiviral Agents/administration & dosage/*therapeutic use
MH  - Benzoxazines/administration & dosage/*therapeutic use
MH  - Cyclopropanes
MH  - Deoxycytidine/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Emtricitabine
MH  - Female
MH  - HIV Infections/*drug therapy/virology
MH  - HIV-1/*drug effects/genetics/metabolism
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nitriles/administration & dosage/*therapeutic use
MH  - Organophosphonates/administration & dosage/*therapeutic use
MH  - Pyrimidines/administration & dosage/*therapeutic use
MH  - RNA, Viral
MH  - Reverse Transcriptase Inhibitors/administration & dosage/*therapeutic use
MH  - Rilpivirine
MH  - Tenofovir
MH  - Time Factors
MH  - Treatment Outcome
MH  - Viral Load/drug effects
MH  - Young Adult
PMC - PMC3985528
EDAT- 2014/03/26 06:00
MHDA- 2014/05/28 06:00
PMCR- 2015/04/01
CRDT- 2014/03/26 06:00
PHST- 2014/03/26 06:00 [entrez]
PHST- 2014/03/26 06:00 [pubmed]
PHST- 2014/05/28 06:00 [medline]
PHST- 2015/04/01 00:00 [pmc-release]
AID - 10.1089/apc.2013.0310 [pii]
AID - 10.1089/apc.2013.0310 [doi]
PST - ppublish
SO  - AIDS Patient Care STDS. 2014 Apr;28(4):168-75. doi: 10.1089/apc.2013.0310. Epub 
      2014 Mar 24.